Sacral nerve stimulation in patients with detrusor overactivity
|
|
- Christiana Gallagher
- 5 years ago
- Views:
Transcription
1 Peer review Sacral nerve stimulation in patients with detrusor overactivity Abstract Detrusor overactivity, particularly with symptoms of urge incontinence, can be a debilitating and embarrassing condition. Sacral nerve stimulation (SNS), or sacral neuromodulation, provides a minimally invasive treatment option for those patients refractory to conventional behavioural and anticholinergic therapy. A review was performed of major studies evaluating the use of SNS for patients with refractory urge incontinence. Factors including therapy technique, efficacy, safety and cost-effectiveness were assessed. The review showed that advances in implant technique have improved both efficacy and safety for SNS. Screening with percutaneous nerve evaluation obtains a positive response in 51-63% of patients. Of the patients that receive permanent implants with a neuromodulating device, complete dryness is obtained in 40-59% of patients and 59-76% of patients report a >50% reduction in incontinence symptoms. The most common adverse events included pain at the implant site and lead migration. A surgical revision rate of % to overcome adverse events was reported with up to 10% requiring permanent explantation. The cost of SNS is estimated at A$9,866 per year of patient complete dryness but long-term cost-effectiveness studies are yet to be performed. In conclusion, SNS appears to be a safe and effective option for patients with refractory urge incontinence. A more detailed cost analysis needs to be conducted before cost-effectiveness can be ascertained. Keywords: urinary incontinence, detrusor overactivity, sacral nerve stimulation, neuromodulation Introduction Sacral nerve stimulation (SNS), or sacral neuromodulation, was introduced in 1994 as a treatment for various voiding and storage dysfunctions 1. Its indications include those of refractory urinary urge incontinence, urge frequency, non-obstructive urinary retention, faecal incontinence, pelvic pain and interstitial cystitis 1-3. This review will focus on the use of SNS in female patients suffering from urinary urge incontinence or detrusor overactivity (DO). In patients with symptoms of DO but no urodynamic testing, the term overactive bladder syndrome is used 4. Yufei Chen The Pelvic Floor Unit, St George Hospital University of New South Wales, Sydney, NSW Competing interests: None declared Acknowledgements: Assistance of A/Prof Kate H Moore, Director, The Pelvic Floor Unit, St George Hospital, University of New South Wales, Sydney & Member (Co-opted) Australian and New Zealand Continence Journal Editorial Committee DO in females is often refractory to conservative management 2, 4, 5. Front-line treatment usually includes behavioural therapy, pelvic floor exercises, dietary modifications (for example, fluid and caffeine reduction) and anticholinergic medication 4. Behavioural therapy such as bladder training has shown varying results, with cure rates ranging from 25% to 97%, possibly related to patient understanding and motivation 5. Anticholinergic medications, although effective, are limited by their side effects, such as a dry mouth and dyspepsia, which can often be intolerable 5, 6. Furthermore, there is a financial barrier to compliance with medical therapy, as most medications in this class are not subsidised within Australia. Intradetrusor injections of botulinum toxin have been shown to be effective in a significant portion of patients with DO, but requires recurrent administration and carries a risk of over paralysis, leading to high rates of intermittent selfcatheterisation 7. Surgical interventions are also available for DO, including bladder augmentation and urinary diversion, but these tend to be saved as a last resort for they are irreversible and are associated with considerable side effects 2, 6, 7. Volume 16 Number 1 Autumn
2 As a minimally invasive procedure, SNS provides a promising intermediate option for patients with DO refractory to standard treatment or where these options are medically contraindicated 8. SNS induces neuromodulation through using mild electrical pulses to continuously stimulate sacral nerves that innervate the lower urinary tract 5. The mechanism underlying the action of SNS on the overactive bladder is thought to arise from stimulation of the A delta afferent fibres of the sacral dorsal root, which simultaneously excite central micturition inhibitory pathways as well as blocking the procontractile effect of neuropeptide release from C fibres. SNS may also stimulate urethral sphincter activity, the contraction of which inhibits detrusor contraction 9, 10. How SNS seems to paradoxically work for patients with non-obstructive urinary retention is poorly understood 11. Implant technique There have been major technical advances in recent years regarding the design and insertion of the implantable pulse generator (IPG). The exclusive supplier of IPGs is currently InterStim TM with their devices allowing external, patientcontrolled regulation of stimulation amplitude within a preprogrammed range 2, 8. The introduction of this patient-directed therapy has reduced patient discomfort and subsequent clinic visits 1, 2. InterStim TM implantation requires a two-stage process. An initial test phase with percutaneous nerve evaluation (PNE) conducted on an out-patient basis is then followed by either permanent implantation or lead removal based on PNE response 4, 11. (Figure 1) which has resulted in an increase in positive screening results 11. The tined-lead approach, with self-anchoring tine elements, allows for a longer screening duration and is less susceptible to lead migration. Furthermore, the tined-lead can be reutilised for the permanent IPG, negating the need for a second stage lead change 2, 5, 12. Since 2002, a minimally invasive procedure has been developed for tined-lead implantation under local anaesthetic, requiring no incision or additional fascial anchoring 12. The nerve supply to the majority of the pelvic organs arises from the S2-4 sacral roots. Despite S2 containing the majority of pudendal afferents, S3 is the target for SNS as its stimulation results in less undesired leg muscle contraction 11. However, pudendal afferents have been found to be limited to solely S2 in 18% 13 of patients which may account for the lack of response to S3 stimulation in certain candidates 11. During PNE, the correct sacral level can be localised by observing patient response; a successful S3 electrode placement should elicit appropriate motor and sensory responses including a bellows movement of the perineum (inward movement of anus and deepening of gluteal cleft), plantar flexion of the great toe and a pulling sensation in the vagina 1, 8, 14. The IPG has traditionally been implanted in the anterior abdominal wall through a flank incision, which required complete turning of the patient during surgery (Figure 2). Scheepens et al. 15 performed a case series of 39 patients PNE originally involved the insertion of an electrode wire through a needle probe, which is subsequently secured by adhesive tapes 1. This has been replaced by the tined-lead test Figure 1. Tined lead approach to PNE. Courtesy of Medtronic, Inc. Figure 2. InterStim TM therapy with device implanted into buttock innervating S3. Courtesy of Medtronic, Inc. 16 Volume 16 Number 1 Autumn 2010
3 Table 1. Efficacy of SNS for DO. Baseline versus last follow-up. Therapy success is defined as a >50% improvement in symptoms over baseline at last follow-up. Follow-up leaks Pad or diapers % patients % patients with duration per day per day completely dry therapy success Schmidt et al. 6 months 9.7 ±6.3 to 2.6 ± ±5.0 to 1.1 ±2.0 52% 76% (1999) * (p<0.0001) (p<0.0001) (at 18 months) (at 18 months) Spinelli et al. 12 months 5.4 ±3.9 to 1.1 ±1.6 NR 59% NR (2001) (p<0.001) Siegel et al. 3 years 11.6 ±6.6 to 5.0 ± ±4.6 to 3.4 ±4.9 NR 59% (2000) (p<0.0001) (p<0.0001) Bosch & Groen 5 years 7.1 to to % 60% (2000) (p=0.0001) (p=0.0001) van Kerrebroeck 5 years 9.6 ±6.0 to 4.7 ±4.9 >5 to 1.8 NR 68% et al. (2007) (p<0.001) (p<0.001) * = RCT, = patients with >90% improvement in symptoms, NR = not reported who underwent buttock implantation of the IPG and found that the procedure was simpler with considerably reduced operating time (from 2.5 to 1.5 hours). More importantly, this led to decreased postoperative pain, fewer infections and a lower reoperation rate 15. Buttock placement has now become the standard approach to IPG implantation, despite a lack of highlevel evidence 2. Efficacy To be eligible for SNS therapy, patients must respond positively to PNE. A successful response is defined in most studies as a greater than 50% improvement in incontinence symptoms by bladder diary over the 3- to 7-day screening period 8, 16. In studies comprised solely of patients with DO, the positive screening rate was 51-63% This screening rate seems to have increased with the use of the tined-lead electrode, but has not been evaluated in patients solely with DO 20. Follow-up duration and study design often varied among studies, making comparisons difficult. A prospective randomised study in patients with refractory urge incontinence showed a significant improvement in all symptoms for patients within the stimulation group after 6 months of SNS (Table 1) 19. Patients allocated to the control group who received 6 months of conventional therapy before crossing over to the stimulation group had significantly worse voiding diary parameters 19. Overall, at 18 months post-implantation, 52% of patients were completely dry, with a further 24% having >50% improvement in symptoms and 57% of patients had eliminated pads with a further 19% having a >50% reduction in pad use 19. A similar RCT by Weil et al. showed a 59% dry rate after 6 months for the implantation group, compared with 5% of patients being dry in the delay group 21. Several other prospective and retrospective studies 3, 8, 19, 22, 23 of patients with refractory DO who underwent SNS also based clinical success on voiding diary parameters (Table 1). Stable, long-term control at 1 and 5 years of all symptoms of DO was shown by two separate studies 3, 23. Only a few studies reported on postoperative urodynamic results. Shaker and Hassouna 24 found that bladder volume at initial urge increased 50% from ml to ml and maximum bladder capacity increased 15% from ml to ml following SNS. At 6-months post implantation, Bosch and Groen 25 found a significant increase in bladder volume at normal desire (213ml to 291ml; p=0.04) and a reduction in the severity of unstable detrusor contractions. Despite the general improvement in urodynamic variables, it has been shown to correlate poorly with symptomatic success 25, 26. Another measure of outcome is patient assessment of quality of life (QoL). Amundsen et al. evaluated patients using the sevenitem Incontinence Impact Questionnaire from with higher scores indicating a negative impact on QoL. They found a significant post-implantation drop in score from 74.3 to 6.8 in 18 Volume 16 Number 1 Autumn 2010
4 Table 2. Effect on QoL scores in patients who underwent SNS for DO. Baseline versus last follow-up. Follow-up duration QoL score (0 to 100) Amundsen et al. (2005) 29 months (range 8 to 48) 74.3 to to 16.6 (patients age <55) (patients age >55) Spinelli et al. (2001) 12 months 33.1 to 69.6 (p<0.001) Aboseif et al. (2007) 18 months 34.4 ±22.8 to 83.8 ± 16.6 (p<0.01) = high score is worse, = higher score is better younger patients and from 82.2 to 16.6 in patients older than 55 (Table 2). Two studies with separate incontinent specific questionnaires where 0 corresponded to poor QoL and 100 to no impact on QoL from incontinence both revealed a significant improvement in scores following SNS 22, 27 (Table 2). Adverse events Despite the minimally-invasive nature of SNS, it is not without its risks and side effects. Adverse events can accompany the initial test stimulation procedure or the IPG implantation. In a study comprising 914 test stimulation procedures, 166 (18.2%) had an associated adverse event 8. The most common issues were lead migration (11.8%), technical problems including incorrect lead placement (2.6%) and pain (2.1%) 8. Adverse events following IPG implantation occur in up to 71% of patients 2, 3. Common complications include new pain or undesirable change in sensation (27-42%) pain at the implant site (21-27%), lead migration (5-10%), infection (6-8%), bowel dysfunction (3-10%) and mechanical problems with the IPG device (2-6%) 2, 3, 8. Adverse effects on bowel function were more often reported in studies with patients aged over 75, suggesting that age affects the clinical outcomes of SNS 14. There were no severe or irreversible adverse events reported 2, 3, 8. Reoperation is often needed to overcome adverse events unable to be managed by antibiotics and local wound care 14, 27. A high overall surgical revision rate of % has been reported by several studies 2, 3, 8. In up to 10% of patients, permanent explantation of the IPG was required 3. Reoperations also occur for battery depletion. Expected battery life for the InterStim TM device is 6-10 years, after which time the pacemaker portion of the device needs to be replaced 7. By itself, this is a fairly small procedure but undoubtedly carries with it further risks. In view of the reported complications, one needs to realise that, in most studies, the safety data often grouped together patients of both genders with diagnoses including urge incontinence, frequency, interstitial cystitis and urinary retention. It may be argued that pooling of data may be justified based on the identical nature of the device and procedure for all patient groups and in one study no significant difference in safety profile was found between the patients with urinary urge incontinence, urgency-frequency and non-obstructive urinary retention 8. Cost-effectiveness Healthcare economics forms the crux of many treatment decisions, but few studies have looked at the cost-effectiveness of SNS. Aboseif et al. 27 conducted a retrospective study of patients who had received InterStim TM therapy, comparing healthcare costs for the year before and after implantation. They found that following InterStim TM insertion, there was a significant decrease per patient in outpatient visit expenses for urinary symptoms (US$994 to US$265), therapeutic and diagnostic procedures including cystoscopy and urodynamics (US$733 to US$59) as well as medication costs (US$693 to US$483) 27. This is in addition to the significant cost of multiple failed therapies which these patients would have undergone prior to undergoing SNS. These figures do not account for the indirect and intangible costs (including loss of productivity and QoL) that form a considerable burden in patients with urinary incontinence 28. However, considering the success of SNS and improvement in patient satisfaction, these costs are likely to be also reduced considerably 1. The cost-benefits of SNS are further improved by the initial test stimulation screening which identifies responders suitable for implantation 1. Long-term cost-benefit research has not yet been performed 27. Longitudinal studies are needed to incorporate the considerable up-front costs of surgical implantation (in excess of A$23,000 for a successful PNE and InterStim TM implantation 29 ) into the true cost-benefit analysis of SNS over time. A government assessment report performed a cost-effectiveness evaluation of SNS for DO estimating a cost of A$9,866 per additional year of patient complete dryness 29. This figure did not take into account patients who achieve partial improvements in urinary symptoms. 20 Volume 16 Number 1 Autumn 2010
5 There is no comparative cost data for SNS versus other treatment options 29. Future long-term cost comparisons between a single SNS operation versus recurrent botulinum injections may be valuable as they both provide minimally-invasive options for patients with urinary incontinence refractory to front-line treatments. Conclusion DO is an increasingly common diagnosis, due to both growing public awareness and the ageing population. Conservative treatments have been found to be generally effective, but in patients whose symptoms are refractory to this approach, SNS provides an alternative option to more invasive surgical procedures. The techniques behind SNS have evolved over the past decade to make it a quick and safe procedure. SNS has been shown to have long-term efficacy in terms of reducing symptoms of urge incontinence and improving quality of life. The recent approval by the Australian Therapeutic Goods Administration of SNS for the treatment of refractory urge incontinence will now allow physicians to offer this therapy to patients who have failed conservative measures. References 1. Shaker H & Hassouna M. Sacal Root Neuromodulation in the Treatment of Various Voiding and Storage Problems. Int Urogynecol J 1999; 10: van Voskuilen A, Oerlemans D, Weil E, de Bie R & van Kerrebroeck P. Long Term Results of Neuromodulation by Sacral Nerve Stimulation for Lower Urinary Tract Symptoms: A Retrospective Single Center Study. Eur Urol 2006; 49: van Kerrebroeck P, van Voskuilen A, Heesakkers J et al. Results of Sacral Neuromodulation Therapy for Urinary Voiding Dysfunction: Outcomes of a Prospective, Worldwide Clinical Study. J Urol 2007; 178: Kohli N & Patterson D. InterStim Therapy: A Contemporary Approach to Overactive Bladder. Rev Obstet Gynecol 2009; 2(1): Yamanishi T, Kamai T & Yoshida K. Neuromodulation for the treatment of urinary incontinence. Int J Urol 2008; 15: Chartier-Kastler E, Bosch J, Perrigot M, Chancellor M, Richard F & Denys P. Long-term results of sacral nerve stimulation (S3) for the treatment of neurogenic refractory urge incontinence related to detrusor hyperreflexia. J Urol 2000; 164: McKertich K. Urinary Incontinence Procedural and Surgical Treatments for Women. Aust Fam Physician 2008; 37(3): Siegel S, Catanzaro F, Dijkema H et al. Long-term result of a multicenter study on sacral nerve stimulation for treatment of urinary urge incontinence, urgency-frequency and retention. Urology 2000; 56(Supplement 6A): Malossi J & Chai T. Sacral Neuromodulation for the Treatment of Bladder Dysfunction. Current Urology Reports 2002; 3: Vignes J, Deloire M & Petry K. Animal Models of Sacral Neuromodulation for Detrusor Overactivity. Neurourol Urodyn 2009; 28: Bosch J. Electrical neuromodulatory therapy in female voiding dysfunction. BJU International 2006; 98(Supplement 1): Spinelli M, Giardiello G, Gerber M, Arduini A, van den Hombergh U & Malaguti S. New Sacral Neuromodulation Lead for Percutaneous Implantation Using Local Anesthesia: Description and First Experience. J Urol 2003; 170(5): Huang J, Deletis V, Vodusek D & Abbott R. Preservation of pudendal afferents in sacral rhizotomies. Neurosurgery 1997; 41: Brazzelli M, Murray A & Fraser C. Efficacy and Safety of Sacral Nerve Stimulation for Urinary Urge Incontinence: A Systematic Review. J Urol 2006; 175: Scheepens W, Weil E, van Koeveringe G et al. Buttock Placement of the Implantable Pulse Generator: A New Implantation Technique for Sacral Neuromodulation A Multicenter Study. Eur Urol 2001; 40: Amundsen C, Romero A, Jamison M & Webster G. Sacral Neuromodulation for Intractable Urge Incontinence: Are There Factors Associated With Cure? Urology 2005; 66(4): Bosch J & Groen J. Sacral (S3) segmental nerve stimulation as a treatment for urge incontinence in patients with detrusor instability: results of chronic electrical stimulation using an implantable neural prosthesis. J Urol 1995; 154: Hasan S, Robon W, Pride A & Neal D. Transcutaneous electrical nerve stimulation and temporary S3 neuromodulation in idiopathic detrusor instability. J Urol 1996; 155: Schmidt R, Jonas U, Oleson K et al. Sacral Nerve Stimulation for Treatment of Refractory Urinary Urge Incontinence. J Urol 1999; 162: Spinelli M, Weil E, Ostardo E et al. New tined lead electrode in sacral neuromodulation: experience from a multicentre European study. World J Urol 2005; 23: Weil E, Ruiz-Cerdá J, Eerdmans P, Janknegt R, Bemelmans B, & van Kerrebroeck P. Sacral root neuromodulation in the treatment of refractory urinary urge incontinence: a prospective randomized clinical trial. Eur Urol 2000; 37(2): Spinelli M, Bertapelle P, Cappellano F et al. Chronic sacral neuromodulation in patients with lower urinary tract symptoms: results from a national register. J Urol 2001; 166(2): Bosch J & Groen J. Sacral nerve neuromodulation in the treatment of patients with refractory motor urge incontinence: long-term results of a prospective longitudinal study. J Urol 2000; 163(4): Shaker H & Hassouna M. Sacral nerve root neuromodulation: effective treatment for refractory urge incontinence. J Urol 1998; 159: Bosch J & Groen J. Neuromodulation: urodynamic effects of sacral (S3) spinal nerve stimulation in patients with detrusor instability or detrusor hyperflexia. Behav Brain Res 1998; 92: Bosch R & Groen J. Complete 5-year follow-up of sacral (S3) segmental nerve stimulation with an implantable electrode and pulse generator in 36 consecutive patients with refractory detrusor overactivity incontinence. Neurourol Urodyn 2002; 21: Aboseif S, Kim D, Rieder J et al. Sacral Neuromodulation: Cost Considerations and Clinical Benefits. Urology 2007; 70(6): Moore K. The costs of urinary incontinence. MJA 2001; 174: Sacral Nerve Stimulation for Urinary Indications: Commonwealth of Australia, Volume 16 Number 1 Autumn
Long Term Results of Neuromodulation by Sacral Nerve Stimulation for Lower Urinary Tract Symptoms: A Retrospective Single Center Study
european urology 49 (2006) 366 372 available at www.sciencedirect.com journal homepage: www.europeanurology.com Female Urology Long Term Results of Neuromodulation by Sacral Nerve Stimulation for Lower
More informationSacral neuromodulation (SNM), using permanent foramen S3 electrode, Early versus late treatment of voiding dysfunction with pelvic neuromodulation
ORIGINAL RESEARCH Early versus late treatment of voiding dysfunction with pelvic neuromodulation Magdy M. Hassouna, MD, PhD; Mohamed S. Elkelini, MD See related article on page 111 Abstract Introduction:
More informationUrodynamic Results of Sacral Neuromodulation Correlate with Subjective Improvement in Patients with an Overactive Bladder
European Urology European Urology 43 (2003) 282±287 Urodynamic Results of Sacral Neuromodulation Correlate with Subjective Improvement in Patients with an Overactive Bladder W.A. Scheepens a, G.A. van
More informationSacral Neuromodulation for Refractory Lower Urinary Tract Dysfunction: Results of a Nationwide Registry in Switzerland
european urology 51 (2007) 1357 1363 available at www.sciencedirect.com journal homepage: www.europeanurology.com Neuro-urology Sacral Neuromodulation for Refractory Lower Urinary Tract Dysfunction: Results
More informationSacral neurostimulation for urinary retention: 10-year experience from one UK centre
Original Articles SACRAL NEUROSTIMULATION FOR URINARY RETENTIONDATTA ET AL. Sacral neurostimulation for urinary retention: 1-year experience from one UK centre Soumendra N. Datta, Charlotte Chaliha, Anubha
More informationSacral neuromodulation for lower urinary tract dysfunction
World J Urol (2012) 30:445 450 DOI 10.1007/s00345-011-0780-2 TOPIC PAPER Sacral neuromodulation for lower urinary tract dysfunction Philip E. V. Van Kerrebroeck Tom A. T. Marcelissen Received: 22 August
More informationContrasting the Percutaneous Nerve Evaluation Versus Staged Implantation in Sacral Neuromodulation
Curr Urol Rep (2010) 11:310 314 DOI 10.1007/s11934-010-0128-2 Contrasting the Percutaneous Nerve Evaluation Versus Staged Implantation in Sacral Neuromodulation Chad Baxter & Ja-Hong Kim Published online:
More informationAUAUpdateSeries. Lesson 19 Volume Treatment of Non-Neurogenic Overactive Bladder with Electrical Stimulation
AUAUpdateSeries Lesson 19 Volume 27 2008 Treatment of Non-Neurogenic Overactive Bladder with Electrical Stimulation Learning Objective: At the conclusion of this continuing medical education activity,
More informationApplications of Neuromodulation of the Lower Urinary Tract in Female Urology
Review Article Neuromodulation of the Lower Urinary Tract in Females International Braz J Urol Vol. 32 (3): 262-272, May - June, 2006 Applications of Neuromodulation of the Lower Urinary Tract in Female
More informationSacral Neuromodulation Beyond Pelvic Pain!!!
Sacral Neuromodulation Beyond Pelvic Pain!!! Dr. Hirachand S Mutagi. Senior Consultant Pain Physician. Head -Sakra World Hospital. Director ReLeaf Pain Services. Rapid advances in neurostimulation therapy
More informationSacral Nerve Neuromodulation/Stimulation
Protocol Sacral Nerve Neuromodulation/Stimulation (70169) Medical Benefit Effective Date: 01/01/14 Next Review Date: 09/14 Preauthorization No Review Dates: 01/08, 11/08, 09/09, 09/10, 09/11, 09/12, 09/13
More informationNeuromodulation and the pudendal nerve
Neuromodulation and the pudendal nerve Stefan De Wachter, MD, PhD, FEBU Professor of Urology University of Antwerpen, Belgium Chairman dept of Urology, UZA Disclosures Consultant speaker: Astellas, Medtronic,
More informationNew PercutaneousTechnique of Sacral Nerve Stimulation Has High Initial Success Rate: Preliminary Results
European Urology European Urology 43 (2003) 70±74 New PercutaneousTechnique of Sacral Nerve Stimulation Has High Initial Success Rate: Preliminary Results Michele Spinelli a,*, Gianluca Giardiello b, Andrea
More informationSACRAL NEUROMODULATION: EVOLUTION OVER TIME
SACRAL NEUROMODULATION: EVOLUTION OVER TIME Anurag K. Das, MD, FACS Director Center for Neuro-urology and Continence Beth Israel Deaconess Medical Center Harvard Medical School Boston, MA First use of
More informationStimulation of the Sacral Anterior Root Combined with Posterior Sacral Rhizotomy in Patients with Spinal Cord Injury. Original Policy Date
MP 7.01.58 Stimulation of the Sacral Anterior Root Combined with Posterior Sacral Rhizotomy in Patients with Spinal Cord Injury Medical Policy Section Issue 12:2013 Original Policy Date 12:2013 Last Review
More informationSacral Nerve Neuromodulation / Stimulation
Sacral Nerve Neuromodulation / Stimulation Policy Number: 7.01.69 Last Review: 2/2018 Origination: 2/2001 Next Review: 2/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage
More informationMEDICAL POLICY SUBJECT: SACRAL NERVE STIMULATION
MEDICAL POLICY 01/16/14, 01/22/15, 03/15/16 PAGE: 1 OF: 8 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy
More informationSacral Nerve Neuromodulation/Stimulation for Pelvic Floor Dysfunction
Medical Policy Manual Surgery, Policy No. 134 Sacral Nerve Neuromodulation/Stimulation for Pelvic Floor Dysfunction Next Review: December 2018 Last Review: June 2018 Effective: July 1, 2018 IMPORTANT REMINDER
More informationRefractory Lower Urinary Tract Symptoms
Sacral Neuromodulation for Treatment of Refractory Lower Urinary Tract Symptoms Alex Kavanagh, PGY3 Mar 30/2011 Goals 1. Define sacral neuromodulation (SNM) and review the clinical implementation 2. Provide
More informationSacral Nerve Neuromodulation/Stimulation
Protocol Sacral Nerve Neuromodulation/Stimulation (70169) Medical Benefit Effective Date: 01/01/16 Next Review Date: 09/18 Preauthorization No Review Dates: 01/08, 11/08, 09/09, 09/10, 09/11, 09/12, 09/13,
More informationSacral Neuromodulation for Dysfunctional Voiders Workshop 1 Monday, August 23, 09:00 10:30
Sacral Neuromodulation for Dysfunctional Voiders Workshop 1 Monday, August 23, 09:00 10:30 Time Time Topic Speaker 09:00 09:05 Introduction to the aims of the workshop and the Magdy Hassouna participants
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Sacral Nerve Neuromodulation / Stimulation Page 1 of 23 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Sacral Nerve Neuromodulation / Stimulation Professional Institutional
More informationSacral Nerve Neuromodulation/Stimulation. Description
Subject: Sacral Nerve Neuromodulation/Stimulation Page: 1 of 17 Last Review Status/Date: September 2015 Sacral Nerve Neuromodulation/Stimulation Description Sacral nerve neuromodulation (SNM), also referred
More informationSacral Nerve Neuromodulation/Stimulation. Description
Subject: Sacral Nerve Neuromodulation/Stimulation Page: 1 of 16 Last Review Status/Date: June 2014 Sacral Nerve Neuromodulation/Stimulation Description Sacral nerve neuromodulation (SNM), also referred
More informationNEUROMODULATION FOR UROGYNAECOLOGISTS
NEUROMODULATION FOR UROGYNAECOLOGISTS Introduction The pelvic floor is highly complex structure made up of skeletal and striated muscle, support and suspensory ligaments, fascial coverings and an intricate
More informationNeuro-urology for the Urogynaecologist and urologist W20, 15 October :00-18:00
Neuro-urology for the Urogynaecologist and urologist W20, 15 October 2012 14:00-18:00 Start End Topic Speakers 14:00 14:05 Introduction to the Workshop Sohier Elneil 14:05 14:25 Neurology of the Bladder
More informationINJINTERNATIONAL. Radiographic Position of the Electrode as a Predictor of the Outcome of InterStim Therapy. Original Article INTRODUCTION
Official Journal of Korean Continence Society / Korean Society of Urological Research / The Korean Children s Continence and Enuresis Society / The Korean Association of Urogenital Tract Infection and
More informationTechnologies and architectures" Stimulator, electrodes, system flexibility, reliability, security, etc."
March 2011 Introduction" Basic principle (Depolarization, hyper polarization, etc.." Stimulation types (Magnetic and electrical)" Main stimulation parameters (Current, voltage, etc )" Characteristics (Muscular
More informationNeuromodulation for pelvic floor dysfunctions: exploring tibial, sacral and pudendal nerve stimulation. W18, 15 October :00-17:00
Neuromodulation for pelvic floor dysfunctions: exploring tibial, sacral and pudendal nerve stimulation. W18, 15 October 2012 14:00-17:00 Start End Topic Speakers 14:00 14:10 Introduction Stefan de Wachter
More informationMEDICAL POLICY SUBJECT: SACRAL NERVE STIMULATION. POLICY NUMBER: CATEGORY: Technology Assessment
MEDICAL POLICY SUBJECT: SACRAL NERVE STIMULATION EFFECTIVE DATE: 11/19/99 PAGE: 1 OF: 9 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Urinary incontinence in women: the management of urinary incontinence in women 1.1 Short title Urinary incontinence in women
More informationThe Presence of Fowler s Syndrome Predicts Successful Long-Term Outcome of Sacral Nerve Stimulation in Women with Urinary Retention
european urology 51 (2007) 229 234 available at www.sciencedirect.com journal homepage: www.europeanurology.com Neuro-urology Voiding Dysfunction The Presence of Fowler s Syndrome Predicts Successful Long-Term
More informationPosterior Tibial Nerve Stimulation
Posterior Tibial Nerve Stimulation Policy Number: Original Effective Date: MM.02.025 01/01/2015 Lines of Business: Current Effective Date: HMO; PPO; QUEST Integration 02/01/2015 Section: Medicine Place(s)
More informationSatisfaction and Patient Experience With Sacral Neuromodulation: Results of a Single Center Sample Survey
Satisfaction and Patient Experience With Sacral Neuromodulation: Results of a Single Center Sample Survey Randall K. Leong, Tom A. Marcelissen, Fred H. Nieman, Rob A. De Bie, Philip E. Van Kerrebroeck*
More informationSexual response in patients treated with sacral neuromodulation for lower. van Voskuilen AC, Oerlemans DJ, Gielen N, Lansen-Koch SM, Weil EH, van
Publicaties Dr. Ernest Weil: Sexual response in patients treated with sacral neuromodulation for lower urinary tract symptoms or fecal incontinence. van Voskuilen AC, Oerlemans DJ, Gielen N, Lansen-Koch
More informationManagement of OAB. Lynsey McHugh. Consultant Urological Surgeon. Lancashire Teaching Hospitals
Management of OAB Lynsey McHugh Consultant Urological Surgeon Lancashire Teaching Hospitals Summary Physiology Epidemiology Definitions NICE guidelines Evaluation Conservative management Medical management
More informationExpanding the Role of Neuromodulation for Overactive Bladder: New Indications and Alternatives to Delivery
Curr Bladder Dysfunct Rep (2011) 6:25 30 DOI 10.1007/s11884-010-0074-3 Expanding the Role of Neuromodulation for Overactive Bladder: New Indications and Alternatives to Delivery Ngoc-Bich Le & Ja-Hong
More informationURINARY INCONTINENCE
Center for Continence Care and Pelvic Medicine What is urinary incontinence? URINARY INCONTINENCE Urinary incontinence is the uncontrollable loss of urine. The amount of urine leaked can vary from only
More informationPOLICIES AND PROCEDURE MANUAL
POLICIES AND PROCEDURE MANUAL Policy: MP091 Section: Medical Benefit Policy Subject: Sacral Nerve Stimulation I. Policy: Sacral Nerve Stimulation II. Purpose/Objective: To provide a policy of coverage
More informationOHTAC Recommendation
OHTAC Recommendation Sacral Nerve Stimulation for the Management of Urge Incontinence, Urgency-Frequency, Urinary Retention and Fecal Incontinence March 2, 2005 1 The Ontario Health Technology Advisory
More informationElectrostimulation Part 3: Bladder dysfunctions
GBM8320 Dispositifs Médicaux Intelligents Electrostimulation Part 3: Bladder dysfunctions Mohamad Sawan et al Laboratoire de neurotechnologies Polystim!!! http://www.cours.polymtl.ca/gbm8320/! mohamad.sawan@polymtl.ca!
More informationMEDICAL POLICY SUBJECT: PERCUTANEOUS POSTERIOR TIBIAL NERVE STIMULATION (PPTNS)
MEDICAL POLICY 03/19/15, 05/17/16 PAGE: 1 OF: 6 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria
More informationGBM8320 Dispositifs Médicaux Intelligents. Electrostimulation. Part 3: Bladder dysfunctions
GBM8320 Dispositifs Médicaux Intelligents Electrostimulation Part 3: Bladder dysfunctions Mohamad Sawan et al Laboratoire de neurotechnologies Polystim!!! http://www.cours.polymtl.ca/gbm8320/! mohamad.sawan@polymtl.ca!
More informationMEDICAL POLICY SUBJECT: PERCUTANEOUS POSTERIOR TIBIAL NERVE STIMULATION (PPTNS) POLICY NUMBER: CATEGORY: Technology Assessment
MEDICAL POLICY SUBJECT: PERCUTANEOUS POSTERIOR Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature generally
More informationAdvanced Care for Female Overactive Bladder & Urinary Incontinence. Department of Urology Kaiser Permanente Santa Rosa
Advanced Care for Female Overactive Bladder & Urinary Incontinence Department of Urology Kaiser Permanente Santa Rosa Goals Participants will: Review normal urinary tract anatomy and function Understand
More informationNeuromodulation for pelvic floor dysfunctions: exploring tibial, sacral and pudendal nerve stimulation. W3, 29 August :00-12:00
Neuromodulation for pelvic floor dysfunctions: exploring tibial, sacral and pudendal nerve stimulation. W3, 29 August 2011 09:00-12:00 Start End Topic Speakers 09:00 09:10 Introduction Stefan De Wachter
More informationInterStim CONSULTATION INFORMATION.
InterStim CONSULTATION INFORMATION www.urologyaustin.com The Urinary System Making An Informed Decision How Does The Urinary System Work? To understand how sacral nerve stimulation works, it is helpful
More informationCorporate Medical Policy
Corporate Medical Policy Percutaneous Tibial Nerve Stimulation for Voiding Dysfunction File Name: Origination: Last CAP Review: Next CAP Review: Last Review: percutaneous_tibial_nerve_stimulation_for_voiding_dysfunction
More informationInitial experience with sacral neuromodulation for the treatment of lower urinary tract dysfunction in Brazil
ORIGINAL ARTICLE Vol. 42 (2): 312-320, March - April, 2016 doi: 10.1590/S1677-5538.IBJU.2014.0603 Initial experience with sacral neuromodulation for the treatment of lower urinary tract dysfunction in
More informationNeuromodulationöSacral, Peripheral and Central: Current Status, Indications, Results and New Developments
EAU Update Series EAU Update Series 2 (2004) 187 194 NeuromodulationöSacral, Peripheral and Central: Current Status, Indications, Results and New Developments Peter Martin Braun*, Christoph Seif, Christof
More informationBladder dysfunction in ALD and AMN
Bladder dysfunction in ALD and AMN Sara Simeoni, MD Department of Uro-Neurology National Hospital for Neurology and Neurosurgery Queen Square, London 10:15 Dr Sara Simeoni- Bladder issues for AMN patients
More informationDaniel S. Engeler 1*, Daniel Meyer 1, Dominik Abt 1, Stefanie Müller 2 and Hans-Peter Schmid 1
Engeler et al. BMC Urology (2015) 15:105 DOI 10.1186/s12894-015-0102-x RESEARCH ARTICLE Open Access Sacral neuromodulation for the treatment of neurogenic lower urinary tract dysfunction caused by multiple
More informationOveractive Bladder Syndrome
Overactive Bladder Syndrome behavioural modifications to pharmacological and surgical treatments Dr Jos Jayarajan Urologist Austin Health, Eastern Health Warringal Private, Northpark Private, Epworth Overactive
More informationSuccessful Therapy of Overactive Bladder Syndrome with Percutaneous Tibial Nerve Stimulation: A Case Report
December, 2017 2017; Vol1; Issue11 http://iamresearcher.online Successful Therapy of Overactive Bladder Syndrome with Percutaneous Tibial Nerve Stimulation: A Case Report Nicole Keller, Seraina Schmid,
More informationCaudal Neuromodulation with the Transforaminal Sacral Electrode (InterStim R ): Experience in a Pain Center Regarding 12 Implants
Original Article Korean J Pain 2016 January; Vol. 29, No. 1: 23-28 pissn 2005-9159 eissn 2093-0569 http://dx.doi.org/10.3344/kjp.2016.29.1.23 Caudal Neuromodulation with the Transforaminal Sacral Electrode
More informationPrognostic Factors for Successful Percutaneous Tibial Nerve Stimulation
european urology 49 (2006) 360 365 available at www.sciencedirect.com journal homepage: www.europeanurology.com Female Urology Prognostic Factors for Successful Percutaneous Tibial Nerve Stimulation M.R.
More informationPosterior Tibial Nerve Stimulation for Treating Neurologic Bladder in Women: a Randomized Clinical Trial
ORIGINAL ARTICLE Posterior Tibial Nerve Stimulation for Treating Neurologic Bladder in Women: a Randomized Clinical Trial Tahereh Eftekhar 1, Nastaran Teimoory 1, Elahe Miri 1, Abolghasem Nikfallah 2,
More informationVague symptoms. Unexpected flares.
PELVIC FLOOR DYSFUNCTION We need to expand the differential diagnosis for chronic pelvic pain to include pelvic myofascial pain Amie Kawasaki, MD Dr. Kawasaki is Fellow in the Division of Female Pelvic
More informationObjectives. Prevalence of Urinary Incontinence URINARY INCONTINENCE: EVALUATION AND CURRENT TREATMENT OPTIONS
URINARY INCONTINENCE: EVALUATION AND CURRENT TREATMENT OPTIONS Lisa S Pair, MSN, CRNP Division of Urogynecology and Pelvic Reconstructive Surgery Department of Obstetrics and Gynecology University of Alabama
More informationClinical Policy: Urinary Incontinence Devices and Treatments
Clinical Policy: Reference Number: CP.MP.142 Last Review Date: 03/18 See Important Reminder at the end of this policy for important regulatory and legal information. Coding Implications Revision Log Description
More informationMr. GIT KAH ANN. Pakar Klinikal Urologi Hospital Kuala Lumpur.
Mr. GIT KAH ANN Pakar Klinikal Urologi Hospital Kuala Lumpur drgitka@yahoo.com 25 Jan 2007 HIGHLIGHTS Introduction ICS Definition Making a Diagnosis Voiding Chart Investigation Urodynamics Ancillary Investigations
More informationCorporate Medical Policy
Corporate Medical Policy Sacral Nerve Neuromodulation/Stimulation for Pelvic Floor Dysfunction File Name: Origination: Last CAP Review: Next CAP Review: Last Review: sacral_nerve_neuromodulation_stimulation_for_pelvic_floor_dysfunction
More information03/13/18. A. Symptoms lasting for greater than or equal to 12 months that have resulted to significant impairment in activities of daily living; and
Reference #: MC/I008 Page: 1 of 5 PRODUCT APPLICATION: PreferredOne Administrative Services, Inc. (PAS) ERISA PreferredOne Administrative Services, Inc. (PAS) Non-ERISA PreferredOne Community Health Plan
More informationDescription. Section: Surgery Effective Date: October 15, 2014 Subsection: Surgery Original Policy Date: December 6, 2012 Subject:
Last Review Status/Date: September 2014 Page: 1 of 10 Description Posterior tibial nerve stimulation (PTNS) is a technique of electrical neuromodulation used for treating voiding dysfunction. The tibial
More informationProlapse & Urogynaecology. Hester Mannion and Fabi Sica
Prolapse & Urogynaecology Hester Mannion and Fabi Sica Take home messages Prolapse and associated incontinence is very common It has a devastating effect on the QoL of the patient and their partner Strategies
More informationTuesday 24 June Poster Session 1: Voiding Dysfunction Chairmen: C. Chapple and L. Stewart
Tuesday 24 June 10.30 11.30 Poster Session 1: Voiding Dysfunction Chairmen: C. Chapple and L. Stewart P001 Can oral antibiotic prophylaxis reduce the rate of infection after conventional urodynamic studies?
More informationINCONTINENCE. Continence and Pelvic Floor Rehabilitation TYPES OF INCONTINENCE STRESS INCONTINENCE STRESS INCONTINENCE STRESS INCONTINENCE 11/08/2015
INCONTINENCE Continence and Pelvic Floor Rehabilitation Dr Irmina Nahon PhD Pelvic Floor Physiotherapist www.nahonpfed.com.au Defined as the accidental and inappropriate passage of urine or faeces (ICI
More informationUniversity College Hospital at Westmoreland Street. Percutaneous Tibial Nerve Stimulation (PTNS)
University College Hospital at Westmoreland Street Percutaneous Tibial Nerve Stimulation (PTNS) Urology Directorate If you need a large print, audio or translated copy of this document, please contact
More informationThe cost of the Axonics sacral neuromodulation system is 475 for the trial phase, 9,210 for a
pat hways Axonics sacral al neuromodulation system for overactive bladder and faecal incontinence Medtech innovation briefing Published: 10 December 2018 nice.org.uk/guidance/mib164 Summary The technology
More informationUrinary Aspects of Multiple Sclerosis chronic condition with innovative treatment strategies. Dr. Boris Friedman May 2, 2012 OBJECTIVES
Urinary Aspects of Multiple Sclerosis chronic condition with innovative treatment strategies Dr. Boris Friedman May 2, 2012 OBJECTIVES 1) Definition and classification of MS 2) Interventional radiology
More informationConservative Management of Functional Bowel & Pelvic Floor Disorders
Conservative Management of Functional Bowel & Pelvic Floor Disorders Kathy Davis PhD BSc(Hons)SRN Specialist Nurse Consultant Parkside Hospital & Minerva Medical Clinic Overview Burden of disease Aims
More informationBotulinum Toxin Injection for OAB: Indications & Technique
Classification of LUTS Botulinum Toxin Injection for OAB: Indications & Technique Sherif Mourad, MD Professor of Urology, Ain Shams University General Secretary of International Continence President of
More informationA Clinical Study of Electroacupuncture on an Overactive Bladder
2004. Vol. 25. No. 4. 220-225 Korean Journal of Oriental Medicine Original Articles A Clinical Study of Electroacupuncture on an Overactive Bladder Jong-Deog Kim, Kyung-Tai Kim, Eun-Jung Kim, Ji-Chul Jung,
More informationNATIONAL INSTITUTE FOR CLINICAL EXCELLENCE SCOPE. Urinary incontinence: the management of urinary incontinence in women
NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE 1 Guideline title SCOPE Urinary incontinence: the management of urinary incontinence in women 1.1 Short title Urinary incontinence 2 Background a) The National
More informationKathleen C. Kobashi, MD, FACS Head, Section of Urology and Renal Transplantation Virginia Mason Medical Center, Seattle, WA
Kathleen C. Kobashi, MD, FACS Head, Section of Urology and Renal Transplantation Virginia Mason Medical Center, Seattle, WA Disclosures Advisory Board and/or Speaker Allergan Medtronic Astellas AUA Guidelines
More informationSecond-line Treatment for OAB
Patient Information English 35 Second-line Treatment for OAB The underlined terms are listed in the glossary. Sometimes the drugs your doctor prescribed do not improve your overactive symptoms (OAB). In
More informationMedical Policy Title: Radiofrequency ARBenefits Approval: 10/19/2011
Medical Policy Title: Radiofrequency ARBenefits Approval: 10/19/2011 Treatment, Urinary Stress Incontinence, Transurethral Effective Date: 01/01/2012 Document: ARB0359 Revision Date: Code(s): 53860 Transurethral
More informationNeuromodulation in neurogenic bladder
Review Article Neuromodulation in neurogenic bladder Melissa T. Sanford, Anne M. Suskind Department of Urology, University of California, San Francisco, CA, USA Contributions: (I) Conception and design:
More informationUrogynecology Office. Can You Hold? An Update on the Treatment of OAB. Can You Hold? Urogynecology Office
Urogynecology Office Urogynecology Office Can You Hold? An Update on the Treatment of OAB Can You Hold? Karen Noblett, MD Professor and Chair Department of OB/GYN University of California, Riverside Disclosures
More informationOveractive bladder syndrome (OAB)
Service: Urology Overactive bladder syndrome (OAB) Exceptional healthcare, personally delivered What is OAB? An overactive bladder or OAB is where a person regularly gets a sudden and compelling need or
More informationBotulinum Toxin: Applications in Urology
Botulinum Toxin: Applications in Urology Dr. Lee Jonat, PGY-4 Department of Urologic Sciences University of British Columbia Outline Mechanism of Action Technical Considerations Adverse Events Neurogenic
More informationCoding for Sacral Neuromodulation
301.273.0570 Fax 301.273.0778 Coding for Sacral Neuromodulation Sacral Neuromodulation (SNS) is a widely used technique in Female Pelvic Medicine and Reconstructive Surgery (FPMRS), with several FDA-approved
More informationPosterior Tibial Nerve Stimulation for Voiding Dysfunction
Posterior Tibial Nerve Stimulation for Voiding Dysfunction Corporate Medical Policy File name: Posterior Tibial Nerve Stimulation for Voiding Dysfunction File code: UM.NS.05 Origination: 8/2011 Last Review:
More informationPercutaneous Tibial Nerve Stimulation
Percutaneous Tibial Nerve Stimulation Policy Number: 7.01.106 Last Review: 11/2018 Origination: 5/2008 Next Review: 5/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) may provide coverage
More informationClinical Study Predictors of Response to Intradetrusor Botulinum Toxin-A Injections in Patients with Idiopathic Overactive Bladder
Advances in Urology Volume 2009, Article ID 328364, 4 pages doi:10.1155/2009/328364 Clinical Study Predictors of Response to Intradetrusor Botulinum Toxin-A Injections in Patients with Idiopathic Overactive
More informationBEST PRACTICE ADVOCACY CENTRE NEW ZEALAND SCOPE. Urinary incontinence in women: the management of urinary incontinence in women
BEST PRACTICE ADVOCACY CENTRE NEW ZEALAND SCOPE 1 Guideline title Urinary incontinence in women: the management of urinary incontinence in women 2 Guideline Contextualisation This is a contextualisation
More informationUrogynecology in EDS. Joan L. Blomquist, MD Greater Baltimore Medical Center August 2018
Urogynecology in EDS Joan L. Blomquist, MD Greater Baltimore Medical Center August 2018 One in three like me Voiding Issues Frequency/Urgency Urinary Incontinence neurogenic bladder Neurologic supply
More information2/9/2008. Men Women. Prevalence of OAB. Men: 16.0% Women: 16.9% Prevalence (%) < Age (years)
Definition Botox for Overactive Bladder Donna Y. Deng Assistant Professor UCSF Department of Urology Urinary urgency With or without urge incontinence Usually with frequency & nocturia International Continence
More informationSpinal Cord Injury. R Hamid Consultant Neuro-Urologist London Spinal Injuries Unit, Stanmore & National Hospital for Neurology & Neurosurgery, UCLH
Spinal Cord Injury R Hamid Consultant Neuro-Urologist London Spinal Injuries Unit, Stanmore & National Hospital for Neurology & Neurosurgery, UCLH SCI 800 1000 new cases per year in UK Car accidents 35%
More informationMedical Review Criteria Implantable Neurostimulators
Medical Review Criteria Implantable Neurostimulators Subject: Implantable Neurostimulators Effective Date: April 14, 2017 Authorization: Prior authorization is required for covered implantable stimulators
More informationSpinal Cord (2014) 52, & 2014 International Spinal Cord Society All rights reserved /14
(214) 52, 241 245 & 214 International Society All rights reserved 162-49/14 www.nature.com/sc ORIGINAL ARTICLE Sacral neuromodulation for neurogenic non-obstructive urinary retention in incomplete spinal
More informationGuidelines on Neurogenic Lower Urinary Tract Dysfunction
Guidelines on Neurogenic Lower Urinary Tract Dysfunction (Text update March 2009) M. Stöhrer (chairman), B. Blok, D. Castro-Diaz, E. Chartier- Kastler, P. Denys, G. Kramer, J. Pannek, G. del Popolo, P.
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Posterior Tibial Nerve Stimulation Page 1 of 25 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Posterior Tibial Nerve Stimulation Professional Institutional Original
More informationGI Physiology - Investigating and treating patients with pelvic floor dysfunction. Lynne Smith Department of GI Physiology NGH Sheffield
GI Physiology - Investigating and treating patients with pelvic floor dysfunction Lynne Smith Department of GI Physiology NGH Sheffield Aims o o o To give an overview of lower GI investigations To demonstrate
More informationPercutaneous Tibial Nerve Stimulation for Overactive Bladder Symptoms. Patient Information Leaflet
Percutaneous Tibial Nerve Stimulation for Overactive Bladder Symptoms Patient Information Leaflet About this leaflet The information provided in this leaflet should be used as a guide. There may be some
More informationSacral neuromodulation for the treatment of urinary bladder dysfunction: mechanism of action and future directions
For reprint orders, please contact: reprints@futuremedicine.com Sacral neuromodulation for the treatment of urinary bladder dysfunction: mechanism of action and future directions Bertil FM Blok *,1 1 Department
More informationThe Praxis FES System and Bladder/Bowel Management in Patients with Spinal Cord Injury
The Praxis FES System and Bladder/Bowel Management in Patients with Spinal Cord Injury Brian J. Benda 1, Thierry Houdayer 2, Graham Creasey 3, Randal R. Betz 1, Brian T. Smith 1 *, Therese E. Johnston
More informationSacral nerve stimulation lead implantation using the o-arm
Hellström et al. BMC Urology 2013, 13:48 TECHNICAL ADVANCE Open Access Sacral nerve stimulation lead implantation using the o-arm Pekka A Hellström, Jani Katisko, Pertti Finnilä and Markku H Vaarala *
More informationVarious Types. Ralph Boling, DO, FACOG
Various Types Ralph Boling, DO, FACOG The goal of this lecture is to increase assessment and treatment abilities for physicians managing urinary incontinence (UI) patients. 1. Effectively communicate with
More informationManaging urinary morbidity after brachytherapy. Kieran O Flynn Department of Urology, Salford Royal Foundation Trust, Manchester
Managing urinary morbidity after brachytherapy Kieran O Flynn Department of Urology, Salford Royal Foundation Trust, Manchester Themes Can we predict urinary morbidity? Prevention of urinary morbidity
More information